Cargando…

The Evolution of Risk Assessment in Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a chronic debilitating disease that carries an unacceptably high morbidity and mortality rate despite improved survival with modern therapies. The combination of several modifiable and nonmodifiable variables yields a robust risk assessment across various ava...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murthy, Sandhya, Benza, Raymond
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Houston Methodist DeBakey Heart & Vascular Center 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298117/ https://www.ncbi.nlm.nih.gov/pubmed/34326933 http://dx.doi.org/10.14797/LRPR7655

Ejemplares similares

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes
por: Burger, Charles D, et al.
Publicado: (2017)

Pregnancy in Pulmonary Arterial Hypertension: A Multidisciplinary Approach
por: Daraz, Yasmeen, et al.
Publicado: (2022)

Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review
por: Wesley Milks, Michael, et al.
Publicado: (2021)

Risk assessment in patients with functional class II pulmonary arterial hypertension: Comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score
por: Sahay, Sandeep, et al.
Publicado: (2020)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Risk assessment in pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2016)

Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension
por: Verlinden, Nathan J., et al.
Publicado: (2020)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension
por: Joshi, Aditya A., et al.
Publicado: (2018)

Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States
por: Chaturvedi, Abhishek, et al.
Publicado: (2020)

Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19
por: Franco, Veronica, et al.
Publicado: (2020)

Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series
por: Raina, Amresh, et al.
Publicado: (2017)

Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study
por: Benza, Raymond L., et al.
Publicado: (2017)

MicroCT analysis of vascular morphometry: a comparison of right lung lobes in the SUGEN/hypoxic rat model of pulmonary arterial hypertension
por: Faight, Erin M., et al.
Publicado: (2017)

The haemodynamic assessment of patients with pulmonary arterial hypertension
por: Ghio, Stefano
Publicado: (2020)

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
por: Davey, Ryan, et al.
Publicado: (2017)

Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry
por: Chung, Lorinda, et al.
Publicado: (2014)

Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design
por: Benza, Raymond L., et al.
Publicado: (2022)

Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension
por: Benza, Raymond L., et al.
Publicado: (2021)

Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension
por: Caccamo, Marco, et al.
Publicado: (2023)

Pulmonary arterial hypertension
por: Montani, David, et al.
Publicado: (2013)

Assessment of Pulmonary Arterial Hypertension by Magnetic Resonance Imaging
por: Ibrahim, El-Sayed H., et al.
Publicado: (2015)

Risk Stratification in Pulmonary Arterial Hypertension, Update and Perspectives
por: Vraka, Argyro, et al.
Publicado: (2023)

Computational Simulator Models and Invasive Hemodynamic Monitoring as Tools for Precision Medicine in Pulmonary Arterial Hypertension
por: Manzi, Giovanna, et al.
Publicado: (2021)

Incorporation of noninvasive assessments in risk prediction for pulmonary arterial hypertension
por: Quan, Ruilin, et al.
Publicado: (2022)

LGE in pulmonary hypertension predicts clinical events
por: Soma, Siva, et al.
Publicado: (2011)

Non-Invasive Assessment of Endothelial Dysfunction in Pulmonary Arterial Hypertension
por: Dara, Athanasia, et al.
Publicado: (2021)

Prime Time for Proteomics in Pulmonary Arterial Hypertension Risk Assessment?
por: Singh, Navneet, et al.
Publicado: (2022)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013)

The Glycobiology of Pulmonary Arterial Hypertension
por: Vang, Shia, et al.
Publicado: (2022)

Pregnancy in pulmonary arterial hypertension
por: Olsson, Karen M., et al.
Publicado: (2016)

Biomarkers in Pulmonary Arterial Hypertension
por: Hojda, Silvana Elena, et al.
Publicado: (2022)

Interpreting risk reduction in clinical trials for pulmonary arterial hypertension
por: Lajoie, Annie C., et al.
Publicado: (2018)

Pulmonary arterial hypertension: tailoring treatment to risk in the current era
por: Gaine, Sean, et al.
Publicado: (2017)

Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective
por: Koudstaal, Thomas, et al.
Publicado: (2020)

Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases: Insights From Pulmonary Arterial Hypertension
por: Torbicki, Adam, et al.
Publicado: (2019)

Pulmonary arterial hypertension: an update
por: Hoendermis, E. S.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3jkfnl0mj24f0smu2e4elel2oi